DYNABAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dynabac, and when can generic versions of Dynabac launch?
Dynabac is a drug marketed by Lilly Res Labs and is included in one NDA.
The generic ingredient in DYNABAC is dirithromycin. There are two drug master file entries for this compound. Additional details are available on the dirithromycin profile page.
Summary for DYNABAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Clinical Trials: | 4 |
Patent Applications: | 3,161 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DYNABAC at DailyMed |
Recent Clinical Trials for DYNABAC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pharmaceutical Research Unit, Jordan | Phase 1 |
Abdi Ibrahim Ilac San. ve Tic A.S. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for DYNABAC
US Patents and Regulatory Information for DYNABAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly Res Labs | DYNABAC | dirithromycin | TABLET, DELAYED RELEASE;ORAL | 050678-001 | Jun 19, 1995 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |